title: Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
abstract: Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of the current small molecule or antibody-based therapeutics are of limited effectiveness due to the inevitable development of resistance and toxicity to normal tissues. Recombinant immunotoxins are therapeutic molecules consisting of an antibody or receptor ligand joined to a protein cytotoxin, combining the specific targeting of a cancer-expressed receptor with the potent cell killing of cytotoxic enzymes. Over the decades, many bacterial- or plant-based immunotoxins have been developed with the goal of targeting the broad range of cancers reliant upon EGFR overexpression. Many examples demonstrate excellent anti-cancer properties in preclinical development, and several EGFR-targeted immunotoxins have progressed to human trials. This review summarizes much of the past and current work in the development of immunotoxins for targeting EGFR-driven cancers.
authors.affiliation: Biotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 37/5124 Bethesda, MD 20892, USA. nathan.simon@nih.gov.
authors.forename: Nathan
authors.initials: N
authors.lastname: Simon
authors.affiliation: Biotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 37/5124 Bethesda, MD 20892, USA. fitzgerd@helix.nih.gov.
authors.forename: David
authors.initials: D
authors.lastname: FitzGerald
mesh_terms: D000818:Animals; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000922:Immunotoxins; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR; cancer therapeutic; clinical development; immunotoxin